Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for Oxylanthanum Carbonate, OLC, and has set a Prescription Drug User Fee Act, PDUFA, target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease, CKD, on dialysis.